Moderna

MRNANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$69.044 B

$172.94 +12.27%

Close of 21 Sept 2026

Revenue

$1.94B

#1151 by revenue

Earnings

-$2.82B

Loss-making

Shares outstanding

399,235,889

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#1AmgenAMGN$212.6B
#2Gilead SciencesGILD$186.7B
#3ModernaMRNA$69.0B
#4Argenx SeARGX$61.3B
#5Revolution MedicinesRVMD$41.3B

What if Moderna were worth as much as…

Open the what-if tool →

Gold $30.3T

$75,829.99

Per share 438× higher

Bitcoin $1.72T

$4,307.74

Per share 24.9× higher

Nvidia $5.48T

$13,725.87

Per share 79.4× higher

Or at a round number

$100.0B $200.0B $500.0B $1.00T

Where these numbers come from

Share counts and financials for Moderna are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.